Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Down 12.3% – Time to Sell?

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF)’s share price traded down 12.3% during mid-day trading on Thursday . The stock traded as low as $0.37 and last traded at $0.37. 202 shares changed hands during trading, a decline of 95% from the average session volume of 4,229 shares. The stock had previously closed at $0.42.

Sino Biopharmaceutical Stock Down 12.3 %

The business has a fifty day moving average of $0.42 and a 200 day moving average of $0.41.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.